Dataset Information


A  paracrine IGF1/IGF1R-PI3K signaling loop underlies resistance to CSF-1R inhibition in GBM

ABSTRACT: Glioblastoma multiforme (GBM) is the most aggressive form of glioma, and is notorious for its terminal prognosis and lack of responsiveness to current treatment approaches. The brain tumor microenvironment (TME) represents a largely untapped reservoir of therapeutic target options in GBM. Here we have focused on the interplay between glioma cells and tumor-associated macrophages/ microglia (TAMs). TAMs accumulate in the gliomas with disease progression, and depend on colony stimulating factor 1 receptor (CSF-1R) signaling for survival. In a recent study from our laboratory, mice bearing high-grade gliomas were treated with a CSF-1R inhibitor, BLZ945 (Novartis), and tumors regressed significantly after just 7 days of treatment (PMID: 24056773). Here we investigate whether long-term treatment of high-grade gliomas with BLZ945 would result in stable management of disease in a mouse model of proneural GBM. We show that ~44% of mice survived to the trial end point (EP) with minimal disease by MRI and histology, whereas ~56% of mice showed tumor recurrence (Reb). Serial transplantation of rebound tumor cells into naïve animals re-established BLZ945 responsiveness, suggesting a role for the microenvironment in supporting recurrent disease. Indeed, RNA-seq analysis on FACS purified tumor cells and TAMs from EP and Reb tumors showed elevated PI3K signaling in Reb tumors, driven by a heterotypic paracrine interaction between TAM-derived IGF-1 and tumor cell IGF-1R. We performed combination trials to block IGF-1R or downstream PI3K signaling in rebound tumors with BLZ945 treatment, and were able to significantly prolong overall survival. Given that CSF-1R inhibitors are currently in clinical trials for multiple cancer types including for GBM, understanding the molecular mechanisms that underlie non-responsive/ resistant tumors is timely and critical. Overall design: Tumor cells and tumor -associated macrophages (TAMs) were sorted from Vehicle, Endpoint, and Rebound tumors following BLZ945 treatment.

INSTRUMENT(S): Illumina HiSeq 2000 (Mus musculus)

SUBMITTER: Robert L Bowman  

PROVIDER: GSE69104 | GEO | 2016-05-20



altmetric image


The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Quail Daniela F DF   Bowman Robert L RL   Akkari Leila L   Quick Marsha L ML   Schuhmacher Alberto J AJ   Huse Jason T JT   Holland Eric C EC   Sutton James C JC   Joyce Johanna A JA  

Science (New York, N.Y.) 20160501 6288

Macrophages accumulate with glioblastoma multiforme (GBM) progression and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to regress high-grade tumors in animal models of this cancer. However, whether and how resistance emerges in response to sustained CSF-1R blockade is unknown. We show that although overall survival is significantly prolonged, tumors recur in >50% of mice. Gliomas reestablish sensitivity to CSF-1R inhibition upon transplantation, indicating that  ...[more]

Similar Datasets

| GSE80399 | GEO
2013-09-20 | E-GEOD-37475 | ArrayExpress
| GSE37475 | GEO
2010-05-16 | E-GEOD-18295 | ArrayExpress
2009-12-26 | GSE18295 | GEO
| GSE99808 | GEO
| GSE67529 | GEO
2012-05-29 | E-GEOD-35855 | ArrayExpress
2016-07-01 | E-GEOD-79492 | ArrayExpress
2015-04-02 | E-GEOD-67529 | ArrayExpress